[Cellebrite Fourth Quarter 2022 Results Overview](index=1&type=section&id=Cellebrite%20Fourth%20Quarter%202022%20Results%20Overview) [Fourth Quarter 2022 Financial Highlights](index=1&type=section&id=Fourth%20Quarter%202022%20Financial%20Highlights) Cellebrite's Q4 2022 revenue grew 9% to **$74.0 million**, with subscription revenue up 24% and Adjusted EBITDA reaching **$16.1 million** Q4 2022 Key Financial Metrics | Metric | Q4 2022 | YoY Change | | :--- | :--- | :--- | | **Total Revenue** | $74.0 million | +9% | | **Subscription Revenue** | $62.3 million | +24% | | **Adjusted EBITDA** | $16.1 million | N/A | | **Adjusted EBITDA Margin** | 21.8% | N/A | | **GAAP Gross Margin** | 83.6% | N/A | | **GAAP Diluted EPS** | $0.04 | N/A | | **Non-GAAP Diluted EPS** | $0.08 | N/A | - The recurring revenue dollar-based net retention rate was **130%** for the fourth quarter[42](index=42&type=chunk) [Full Year 2022 Financial Highlights](index=1&type=section&id=Full%20Year%202022%20Financial%20Highlights) Full year 2022 revenue grew 10% to **$270.7 million**, with ARR up **33%** to **$249 million**, though Adjusted EBITDA decreased Full Year 2022 Key Financial Metrics | Metric | Full Year 2022 | YoY Change | | :--- | :--- | :--- | | **Total Revenue** | $270.7 million | +10% | | **Subscription Revenue** | $216.0 million | +18% | | **Annual Recurring Revenue (ARR)** | $249 million | +33% | | **Adjusted EBITDA** | $25.9 million | N/A | | **Adjusted EBITDA Margin** | 10% | N/A | | **GAAP Net Income** | $120.8 million | N/A | [Management Commentary](index=1&type=section&id=Management%20Commentary) Management emphasized strong market leadership and a successful subscription model transition, positioning for accelerated 2023 growth and profitability - CEO Yossi Carmil stated the company ended 2022 with solid results, fueled by industry-leading technology and investments in platform innovation and go-to-market strategy[2](index=2&type=chunk) - CFO Dana Gerner highlighted the successful transition to a subscription model, with **84%** of Q4 revenue from subscription licenses and a **33%** annual growth in ARR[22](index=22&type=chunk) - The company is positioned to increase its revenue growth rate and sustain ARR momentum in 2023, while aiming for its long-term EBITDA margin target of **20%** or greater[22](index=22&type=chunk) [Business and Operational Highlights](index=2&type=section&id=Business%20and%20Operational%20Highlights) [Key Business Developments in Q4 2022](index=2&type=section&id=Key%20Business%20Developments%20in%20Q4%202022) Cellebrite secured **29 large deals** including **$14 million** and **$10+ million** contracts, launching new cloud capabilities and partnerships against human trafficking - Closed **29 large deals**, each valued at **$500,000** or more[20](index=20&type=chunk) - Secured major contracts, including a **$14 million** deal with a leading law enforcement agency in Asia and a **$10+ million** deal with a major West European national police force[36](index=36&type=chunk)[59](index=59&type=chunk) - Launched new cloud workplace app collection capability for Cellebrite Endpoint Inspector to improve eDiscovery for corporate investigations[44](index=44&type=chunk) - Partnered with organizations like the GLAA and The Exodus Road to help combat forced labor and human trafficking[37](index=37&type=chunk) [Financial Outlook](index=3&type=section&id=Financial%20Outlook) [Full Year 2023 Guidance](index=3&type=section&id=Full%20Year%202023%20Guidance) Cellebrite projects full year 2023 revenue of **$305-315 million**, ARR of **$300-310 million**, and Adjusted EBITDA of **$35.0-40.0 million** Full Year 2023 Financial Outlook | Metric | 2023 Guidance | YoY Growth | | :--- | :--- | :--- | | **Revenue** | $305 - $315 million | 13% - 16% | | **ARR** | $300 - $310 million | 21% - 25% | | **Adjusted EBITDA** | $35.0 - $40.0 million | N/A | | **Adjusted EBITDA Margin** | 11% - 13% | N/A | [Financial Statements](index=7&type=section&id=Financial%20Statements) [Condensed Consolidated Statements of Income](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Income) Full year 2022 revenue increased to **$270.7 million**, gross profit rose, operating income decreased, but net income surged to **$120.8 million** due to financial income Full Year Income Statement Highlights (in thousands) | Account | 2022 | 2021 | | :--- | :--- | :--- | | **Total Revenue** | $270,651 | $246,246 | | **Gross Profit** | $219,905 | $203,689 | | **Operating Income** | $1,044 | $13,822 | | **Net Income** | $120,805 | $71,396 | [Condensed Consolidated Balance Sheets](index=8&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of December 31, 2022, total assets increased to **$403.3 million**, liabilities decreased, and shareholders' equity turned positive to **$73.9 million** Balance Sheet Summary (in thousands) | Account | Dec 31, 2022 | Dec 31, 2021 | | :--- | :--- | :--- | | **Cash and cash equivalents** | $87,645 | $145,973 | | **Total Assets** | $403,293 | $339,783 | | **Total Liabilities** | $329,428 | $413,130 | | **Total Shareholders' Equity (Deficiency)** | $73,865 | $(73,347) | [Condensed Consolidated Statements of Cash Flow](index=11&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flow) Full year 2022 operating cash flow was **$20.6 million**, with a **$56.7 million** net decrease in cash due to investing activities Full Year Cash Flow Summary (in thousands) | Account | 2022 | 2021 | | :--- | :--- | :--- | | **Net cash provided by operating activities** | $20,577 | $36,052 | | **Net cash (used in) provided by investing activities** | $(91,231) | $45,226 | | **Net cash provided by (used in) financing activities** | $13,970 | $(68,397) | | **Net (decrease) in cash and cash equivalents** | $(56,684) | $12,881 | [Reconciliation of GAAP to Non-GAAP Financial Information](index=13&type=section&id=Reconciliation%20of%20GAAP%20to%20Non-GAAP%20Financial%20Information) This section reconciles GAAP to non-GAAP financial measures, adjusting for non-cash items, with full year 2022 GAAP net income of **$120.8 million** adjusted to **$19.7 million** non-GAAP Reconciliation of Net Income to Adjusted EBITDA (Full Year, in thousands) | Account | 2022 | 2021 | | :--- | :--- | :--- | | **Net Income (GAAP)** | $120,805 | $71,396 | | **Financial expense (income), net** | $(119,716) | $(68,483) | | **Tax expense (income)** | $(45) | $10,909 | | **Share based compensation** | $13,708 | $6,480 | | **Depreciation & Amortization** | $9,194 | $7,007 | | **Adjusted EBITDA (Non-GAAP)** | $25,906 | $47,905 | [Supplemental Information](index=4&type=section&id=Supplemental%20Information) [Key Performance Indicators (KPIs)](index=5&type=section&id=Key%20Performance%20Indicators%20(KPIs)) The company uses Annual Recurring Revenue (ARR) and Dollar-Based Net Retention Rate (NRR) as key performance indicators for subscription and customer revenue growth - Annual Recurring Revenue (ARR) is defined as the annualized value of active term-based subscription license contracts and maintenance contracts in effect at the end of a period[25](index=25&type=chunk) - Dollar-based Net Retention Rate (NRR) measures recurring revenue growth from existing customers over a trailing four-quarter period[66](index=66&type=chunk) [Non-GAAP Financial Information Explanation](index=4&type=section&id=Non-GAAP%20Financial%20Information%20Explanation) Cellebrite uses non-GAAP measures to provide a clearer view of operational performance by excluding non-cash and acquisition-related adjustments - The company uses non-GAAP measures to provide a more meaningful comparison of its operational performance from period to period[8](index=8&type=chunk)[63](index=63&type=chunk) - Adjustments typically exclude non-cash expenses like share-based compensation and amortization of intangible assets, as well as acquisition-related costs and the impact of financial instrument remeasurement[8](index=8&type=chunk)[24](index=24&type=chunk)[48](index=48&type=chunk) [Forward-Looking Statements](index=6&type=section&id=Forward-Looking%20Statements) This report contains forward-looking statements subject to various risks and uncertainties, including technological changes, market competition, and macroeconomic conditions - The document includes forward-looking statements regarding revenues, earnings, performance, and strategies, which are subject to risks and uncertainties[11](index=11&type=chunk) - Key risk factors include the ability to keep pace with technology, dependence on law enforcement and government agencies, intense competition, and macroeconomic conditions[11](index=11&type=chunk)

::* Cellebrite Q3 '22 Earnings Call 17 November 2022 Disclaimer This presentation has been prepared by Cellebrite DI Ltd. (the "Company") solely for informational purposes. It is not, and should not be assumed to be, complete. This presentation is not an offer to sell securities, nor is it a solicitation of an offer to buy securities. This presentation is not directed at, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country ...

Cellebrite DI Ltd. (NASDAQ:CLBT) Q3 2022 Earnings Conference Call November 17, 2022 8:30 AM ET Company Participants Sabrina Mathews - IR Yossi Carmil - CEO Dana Gerner - CFO Conference Call Participants Jonathan Ho - William Blair Tomer Zilberman - Bank of America Mike Cikos - Needham Louie DiPalma - William Blair Operator Good day and thank you for standing by. Welcome to the Cellebrite Q3 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there ...

Exhibit 99.1 Cellebrite Announces Third Quarter 2022 Results ARR of $232 million, up 35% year-over-year Third Quarter revenue of $71.7 million, Increase 9% year-over-year PETAH TIKVA, ISRAEL, and TYSONS CORNER, VA, November 17, 2022 – Cellebrite (NASDAQ: CLBT), a global leader in Digital Intelligence ("DI") solutions for the public and private sectors, today announced financial results for the three and nine months ending September 30, 2022. "We are pleased to report a solid third quarter, delivering strong ...

Exhibit 99.1 Cellebrite DI Ltd.and its Subsidiaries INTERIM CONSOLIDATED BALANCE SHEETS (U.S Dollars in thousands, except share and per share data) INTERIM CONSOLIDATED BALANCE SHEETS U.S. dollar in thousands (except share and per share data) CONSOLIDATED FINANCIAL STATEMENTS CELLEBRITE DI LTD. AND ITS SUBSIDIARIES INTERIM CONSOLIDATED FINANCIAL STATEMENT AS OF JUNE 30, 2022 UNAUDITED INDEX | --- | --- | |----------------------------------------------------------------------------------|-------| | | Page | ...

Cellebrite DI Ltd. (NASDAQ:CLBT) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Anat Earon-Heilborn - Vice President, Investor Relations Yossi Carmil - Chief Executive Officer Dana Gerner - Chief Financial Officer Conference Call Participants Mike Cikos - Needham & Company Jonathan Ho - William Blair & Company Shaul Eyal - Cowen Jamie Shelton - Deutsche Bank Louie DiPalma - William Blair & Company Operator Good day and thank you for standing by. Welcome to the Cellebrite Q2 ...

:: Cellebrite Investor Presentation May 2022 Disclaimer Use of Non-GAAP Financial Measures This Presentation includes non-BAAP financial measures. Cellebrite believes hat lhese non-BAAP mossures are useful to investors for two principal reasons. First, Dollohrid investors in comparing performance over various reporting periods on a consisient basis by removing from operaling results te impact of liems that do not reflect ore opera measures are used by Cellebrite s management to assess is performance. Celebr ...

Cellebrite DI Ltd. (NASDAQ:CLBT) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Anat Earon-Heilborn - Vice President, Investor Relations Yossi Carmil - Chief Executive Officer Dana Gerner - Chief Financial Officer Conference Call Participants Tomer Zilberman - Bank of America Merrill Lynch Jamie Shelton - Deutsche Bank Louie DiPalma - William Blair & Company Operator Good day and thank you for standing by. Welcome to the Cellebrite Q1 '22 Earnings Call. At this time, all parti ...

් Cellebrite Q1 '22 Earnings Call 12 May 2022 Disclaimer Use of Non-GAAP Financial Measures This Presentation includes non-GAAP financial measures. Cellebrite believes that these non-GAAP measures are useful to investors for two principal reasons. First, Collebri believes these measures may assist investors in comparing performance over various reporting periods on a consistent basis by removing from operating results he impact of items that do not reflect core operating performance. Second, these measures ...

Exhibit 99.1 Cellebrite Announces First Quarter 2022 Results ARR of $201 million, up 33% year-over-year First Quarter revenue of $62.4 million, up 17% year-over-year Reiterates 2022 outlook for 34-42% ARR growth and 16-22% revenue growth PETAH TIKVA, ISRAEL, and TYSONS CORNER, VA, May 12, 2022 – Cellebrite (NASDAQ: CLBT), a global leader in Digital Intelligence ("DI") solutions for the public and private sectors, today announced financial results for the three months ended March 31, 2022. "We are excited to ...